An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment

Novartis Pharmaceuticals1 site in 1 country38 target enrollmentMarch 2011

ConditionsAllergic Asthma

InterventionsOmalizumab

DrugsOmalizumab

Overview

Phase: Phase 3
Intervention: Omalizumab
Conditions: Allergic Asthma
Sponsor: Novartis Pharmaceuticals
Enrollment: 38
Locations: 1
Primary Endpoint: To assess the long-term safety and tolerability of omalizumab by measuring AEs, serious AEs, physical examination, medical history, laboratory assessments and vital signs
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this extension study is to assess the long-term safety and tolerability of omalizumab as an add-on therapy in Japanese pediatric patients (6 to 15 years of age) with inadequately controlled allergic asthma despite current recommended treatment by providing continued treatment with omalizumab to patients who have previously completed the core study.

Registry

clinicaltrials.gov

Start Date

March 2011

End Date

December 2013

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Novartis Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug.

Exclusion Criteria

•Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer.
•Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means; using a highly effective method of birth control; or agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance.
•With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study.
•Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site.

Arms & Interventions

Omalizumab

Intervention: Omalizumab

Outcomes

Primary Outcomes

To assess the long-term safety and tolerability of omalizumab by measuring AEs, serious AEs, physical examination, medical history, laboratory assessments and vital signs

Time Frame: Every 3 months for approximately 2 years

Secondary Outcomes

To explore the efficacy of omalizumab by JPAC questionnaire; JPAC is the Japan Pediatric Asthma Control Program (JPAC)(Every 3 months for approximately 2 years)
To explore the efficacy of omalizumab by QOL questionnaire score (Quality of life questionnaires for pediatric patients with bronchial asthma and their parents or caregivers (Gifu))(Every 3 months for approximately 2 years)
To explore the efficacy of omalizumab by use of asthma long-term control medications(Every 3 months for approximately 2 years)
To explore the efficacy of omalizumab by Pulmonary function (FEV1, FVC, V(・)50, V(・)25 and FEF25-75%)(Every 3 months for approximately 2 years)
To collect the data on the number of hospitalizations, emergency room (ER) visits due to asthma(Every 3 months for approximately 2 years)